Ken Lin
Glaucoma Specialist · Irvine, CANPI 1205153939
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,400 of the $30,118 with a category attached, or 67.7%. 15 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 33.4% of the total. Reporting peaked in 2021 at $14,591 and has fallen 99.8% since, to $24 in 2025.
Across 61 payments — averaging $493.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$10K
- Aerie Pharmaceuticals, Inc.$8K
- Alcon Research LLC$7K
- Bausch & Lomb Americas Inc.$2K
- Microsurgical Technology, Inc.$1K
- AbbVie$567
- plus $1K from 9 others
What the payments were for
- Consulting fees$20,40068%
- Speaking & faculty fees$7,31824%
- Food & beverage$2,1917%
- Education$2091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 7 | $10,067 |
| Aerie Pharmaceuticals, Inc. | 16 | $8,013 |
| Alcon Research LLC | 5 | $7,400 |
| Bausch & Lomb Americas Inc. | 4 | $1,684 |
| Microsurgical Technology, Inc. | 1 | $1,000 |
| AbbVie(2 entities) | 12 | $567 |
| Ivantis, Inc | 1 | $500 |
| Alcon | 5 | $243 |
| Glaukos Corporation | 4 | $218 |
| Stryker | 1 | $169 |
| Ellexiscience | 1 | $146 |
| Relievant Medsystems, Inc. | 1 | $42 |
| Oyster Point Pharma, Inc. | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$7,799
- Rhopressa$7,799
- Phacofragmentation Accessories$2,500
- VYZULTA$1,599
- Healon Viscoelastics$1,300
- Hydrus Microstent$500
- AEQUALIS PERFORM$169
- iStent inject W$164
- MIEBO$149
- XIIDRA$149
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- XEN GLAUCOMA TREATMENT SYSTEM$119
How this compares
$30,118 in reported general payments places this provider in the 80th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 122 | $65,919 |
| RhopressaNetarsudil Mesylate | 116 | $54,248 |
| Alphagan PBrimonidine Tartrate | 93 | $41,191 |
| VyzultaLatanoprostene Bunod | 72 | $25,595 |
| RestasisCyclosporine | 23 | $25,500 |
| RocklatanNetarsudil Mesylat/Latanoprost | 45 | $24,764 |
| Brimonidine Tartrate | 382 | $22,019 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 66 | $14,024 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $12,662 |
| Travoprost | 76 | $12,548 |
| Brinzolamide | 57 | $11,989 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 529 | $11,985 |
| Latanoprost | 988 | $11,331 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 54 | $10,075 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $9,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $567 | $145,272282 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $8,013 | $79,012161 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,684 | $25,59572 claims |
| AlconSimbrinza, Azopt | $243 | $16,72230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Irvine
- Sameh MosaedIrvine$44K
- Austin FoxIrvine$6K
- Andrew SmithIrvine$4K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.